Article | April 27, 2020

How To Pick The Right CDMO For Late-Phase Clinical Trials

By Christy Eatmon, Global SME, Sterile Drug Products, Thermo Fisher Scientific

A Single-Vendor CDMO Eases Communication Flow

For pharmaceutical companies without their own facilities, choosing the right partner for late-phase clinical trials and commercial production is a critical consideration in developing parenteral products. Small contract development and manufacturing organizations (CDMOs) can often provide early-phase material but may not always be able to move through to meet the rigorous demands of late stage and into commercialization. This article examines some of the key criteria for selecting the right CDMO partner and includes a case study that shares some challenges involved in a late-phase technology transfer for a parenteral product.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: